Skip to main content

Table 3 Summary of forest plot for TRAEs (PP ± B vs. PC + B)

From: Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

TRAEs

PP ± B

n/N (%)

PC + B

n/N (%)

Heterogeneity

I2

Heterogeneity P value

RR (95% CI)

P value

Drug–related deaths

9/684 (1.3%)

13/680 (1.9%)

0%

0.845

0.84 (0.52,1.37)

0.491

Grade 3/4 TRAEs

 Anemia

97/684

(14.2%)

23/680 (3.4%)

2.3%

0.359

1.75 (1.58,1.95)

0.000

 Hypertension

15/684

(2.2%)

29/680 (4.3%)

0%

0.546

0.73 (0.49,1.08)

0.117

 Neutropenia

161/684 (23.5%)

267/680 (39.3%)

1.0%

0.364

0.67 (0.59,0.77)

0.000

 Thrombocytopenia

144/684 (21.1%)

42/680 (6.2%)

25.3%

0.262

1.70 (1.47,1.96)

0.000

 Sensory neuropathy

1/684 (0.1%)

26/680 (3.8%)

0%

0.384

0.21 (0.06,0.76)

0.017

 Febrile neutropenia

6/684 (0.9%)

22/680 (3.2%)

0%

0.875

0.47 (0.25,0.90)

0.023

  1. Abbreviation: PP ± B Pemetrexed-platinum with or without bevacizumab; PC + B paclitaxel-carboplatin with bevacizumab; RR Risk ratio; TRAEs Treatment-related adverse events